Oncology – Gastrointestinal
RCT | Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer
20 Jan, 2023 | 14:19h | UTC
Commentary on Twitter
Single centre #RCT of surgery for T3/4 N+ #rectalcancer before or after 8 weeks of CRT
???350 patients
⚖️no difference locoregional recurrence
Distant mets more common in delayed group at 5yrs
DFS and OS similar#some4surgery @SEIQuirurgica @asgbi https://t.co/4evsKNKKK1 pic.twitter.com/CxI0GJdG56— BJS Open (@BjsOpen) October 24, 2022
Study shows patients with circulating tumor DNA are at increased risk of relapse after surgery for resectable colorectal cancer
19 Jan, 2023 | 14:18h | UTCCommentary: Data Support ctDNA as a Prognostic Marker for Recurrence/Benefit in Colorectal Cancer – Cancer Network
Commentary on Twitter
In the observational arm of the CIRCULATE-Japan study, among patients with stage II-IV #ColorectalCancer, those with the presence of circulating #tumorDNA post-tumor resection have a high recurrence risk & are likely to benefit from adjuvant #chemotherapyhttps://t.co/hKlRt1ZW6T
— Nature Medicine (@NatureMedicine) January 17, 2023
Consensus Paper | Management of early-onset colorectal cancer
19 Jan, 2023 | 14:14h | UTC
ACG Clinical Guideline | Diagnosis and management of gastrointestinal subepithelial lesions
18 Jan, 2023 | 14:39h | UTC
M-A | Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival?
17 Jan, 2023 | 13:07h | UTC
RCT | Adjuvant nab-Paclitaxel + Gemcitabine in resected pancreatic ductal adenocarcinoma
10 Jan, 2023 | 14:13h | UTC
RCT | Neoadjuvant chemotherapy with CAPOX vs. chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia
10 Jan, 2023 | 14:09h | UTC
ASCO Guideline | Immunotherapy and targeted therapy for advanced gastroesophageal cancer
9 Jan, 2023 | 14:40h | UTC
Phase 1-2 study | Adagrasib with or without Cetuximab in colorectal cancer with mutated KRAS G12C
9 Jan, 2023 | 14:04h | UTCAdagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Advanced Colorectal Cancer Treatment Targets KRAS Gene With Drug Combo – Memorial Sloan Kettering Cancer Center
Commentary on Twitter
In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with cetuximab, an epidermal growth factor receptor antibody. https://t.co/nCoEPeV9oB pic.twitter.com/FCHxU9WCin
— NEJM (@NEJM) December 21, 2022
M-A | Laparoscopic vs. open pancreatoduodenectomy in patients with periampullary tumors
9 Jan, 2023 | 14:02h | UTCLaparoscopic versus Open Pancreatoduodenectomy in Patients with Periampullary Tumors: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)
Review | Role of AI and digital pathology for colorectal immuno-oncology.
16 Dec, 2022 | 13:11h | UTCRole of AI and digital pathology for colorectal immuno-oncology – British Journal of Cancer
A comprehensive systematic review of colorectal cancer screening clinical practices guidelines and consensus statements.
16 Dec, 2022 | 13:09h | UTC
RCT | Assessment of spleen-preserving hilar lymphadenectomy for advanced proximal gastric cancer without invasion into the greater curvature.
15 Dec, 2022 | 13:30h | UTCAssessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
See also: Visual Abstract and Video Summary
Phase 2 RCT | Immediate surgery vs. short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer.
14 Dec, 2022 | 15:01h | UTCNews Release: Chemotherapy before surgery can improve survival rates in pancreatic cancer patients – University of Liverpool
Commentary on Twitter
New research – Ghaneh et al – Immediate surgery vs short-course neoadjuvant gemcitabine + capecitabine, FOLFIRINOX, or chemoradiotherapy in patients w/ borderline resectable #pancreaticcancer (ESPAC5): a randomised phase 2 trialhttps://t.co/9S1hupyKjg#gitwitter #onctwitter pic.twitter.com/g2jQUAhUSJ
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 14, 2022
Review | Interventional gastroenterology in oncology.
12 Dec, 2022 | 12:46h | UTCInterventional gastroenterology in oncology – CA: A Cancer Journal for Clinicians
Post-trial follow-up | Bursectomy vs. omentectomy alone for resectable gastric cancer.
12 Dec, 2022 | 12:26h | UTCFive-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001) – British Journal of Surgery (link to abstract – $ for full-text)
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
15 Nov, 2022 | 12:52h | UTC
Commentary from the author on Twitter
https://twitter.com/ArndtVogel/status/1590634413377081344
Phase 2 RCT | Efficacy of Bemarituzumab in patients with FGFR2b-selected gastric or gastro-esophageal junction adenocarcinoma.
11 Nov, 2022 | 13:02h | UTCBemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
?Targeting FGFR2b in gastric & gastro-oesophageal junction adenocarcinoma?@TheLancetOncolhttps://t.co/Rc6AGRIf4a
✅FIGHT: FOLFOX6 + plc. vs bemarituzumab
?mPFS: 9.5 vs 7.5 mo, n.s.
?mOS: 19.2 vs 13.5 mo
⛔️eye tox & stomatitis
✅FORTITUDE-101/102 ongoing@myESMO @OncoAlert pic.twitter.com/JTL23o23dY— Arndt Vogel (@ArndtVogel) October 17, 2022
NICE Guideline Update | Colonoscopic surveillance in adults with inflammatory bowel disease or adenomas.
10 Nov, 2022 | 14:16h | UTCRelated:
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
M-A | Efficacy of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer.
4 Nov, 2022 | 13:22h | UTC
Cohort Study | Mental health morbidities and time to cancer diagnosis among adults with colon cancer in England.
3 Nov, 2022 | 13:55h | UTCInvited Commentary: The Interface Between Colon Cancer and Mental Health Morbidities – JAMA Network Open
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
31 Oct, 2022 | 13:51h | UTCRelated Guideline: ASCO Guideline | Treatment of metastatic colorectal cancer.
Cohort Study | Risk factors of pancreatic cancer in patients with Type 2 DM.
31 Oct, 2022 | 13:47h | UTC
Cohort Study | Diverticular disease linked to increased risk of cancer outside the GI tract.
31 Oct, 2022 | 13:33h | UTCCancer risk in patients with diverticular disease: a nationwide cohort study – JNCI: Journal of the National Cancer Institute (link to abstract – $ for full-text)
News Release: Diverticular disease associated with cancer outside gastrointestinal tract – Karolinska Institutet
Expert Consensus | Imaging standardization in metastatic colorectal cancer.
26 Oct, 2022 | 14:36h | UTC